8-K/A: TuHURA Biosciences Amends 8-K Filing to Include Private TuHURA Financials Following Merger

TuHURA Biosciences has amended its previous 8-K filing to incorporate the financial results of the private company, TuHURA, for the periods ending September 30, 2024, and 2023, following its merger with Kintara Therapeutics.

Summary

• TuHURA Biosciences, formerly Kintara Therapeutics, filed an amendment to its original 8-K report to include the financial statements of the private TuHURA company before the merger.
• The amendment includes the Management's Discussion and Analysis of Financial Condition and Results of Operations for private TuHURA for the three and nine months ended September 30, 2024, and 2023.
• Private TuHURA's unaudited interim financial statements as of September 30, 2024, and for the three and nine months ended September 30, 2024, and 2023, are also included.
• TuHURA is a clinical-stage immuno-oncology company focused on developing personalized cancer vaccines and antibody drug conjugates.
• The company has a Special Protocol Assessment agreement with the FDA for a Phase 3 trial of its lead vaccine candidate, IFx-2.0, for Merkel cell carcinoma.
• TuHURA has incurred significant operating losses since inception, with a net loss of $15.7 million for the nine months ended September 30, 2024, and an accumulated deficit of $105.1 million.
• The company's operations are primarily funded through private placements of stock and convertible notes.
• As of September 30, 2024, TuHURA had cash and cash equivalents of $19.6 million.
• TuHURA completed a merger with Kintara Therapeutics on October 18, 2024, which is being accounted for as a reverse recapitalization.
• The company also entered into an exclusivity agreement with Kineta for the potential acquisition of an anti-VISTA antibody, KVA12123, and paid a $5 million fee.
• TuHURA anticipates needing substantial additional funding to support its operations and growth strategy.

Sentiment

Score: 4

Explanation: The document highlights significant financial losses and the need for substantial additional funding, which is concerning. However, the company has a clear development plan and has secured some funding, which provides a glimmer of hope. The sentiment is therefore cautiously negative.

Positives

• TuHURA has a Special Protocol Assessment agreement with the FDA for its lead vaccine candidate, IFx-2.0, which could expedite its approval.
• The company has a Phase 3 trial for IFx-2.0 planned for the first quarter of 2025.
• TuHURA has secured $31,253,000 through convertible notes, providing capital for operations.
• The company has $19.6 million in cash and cash equivalents as of September 30, 2024.
• The merger with Kintara Therapeutics provides access to public markets and potentially more capital.
• TuHURA is collaborating with Kineta on the ongoing KVA12123 VISTA clinical trial program.

Negatives

• TuHURA has incurred significant operating losses, with a net loss of $15.7 million for the nine months ended September 30, 2024.
• The company has an accumulated deficit of $105.1 million.
• TuHURA has not generated any revenue from product sales and does not expect to in the near future.
• The company is dependent on raising additional capital to fund its operations.
• There is a risk that TuHURA may be unable to raise additional funds or enter into other arrangements when needed.
• The $5 million fee paid to Kineta for the exclusivity agreement is non-refundable.
• The company has a history of negative cash flows from operations.

Risks

• TuHURA is dependent on raising additional capital, and there is no guarantee that it will be able to do so on favorable terms or at all.
• The company's operating losses may fluctuate significantly, and it expects to continue to incur losses.
• The development of pharmaceutical products is subject to numerous risks and uncertainties, and TuHURA may not be able to achieve or maintain profitability.
• The company's failure to raise capital could force it to delay, limit, reduce, or terminate its product development or commercialization efforts.
• There is no guarantee that the company will be able to obtain regulatory approval for its product candidates.
• The company is exposed to market risks, including interest rate and inflation risks.
• The company's future clinical development costs may vary significantly based on several factors.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Future Outlook

TuHURA expects to continue to incur operating losses and will need substantial additional funding to support its operations and growth strategy. The company anticipates initiating a Phase 3 trial for IFx-2.0 in the first quarter of 2025 and expects topline data 6 to 7 months after the last patient is enrolled. TuHURA believes its existing cash and cash equivalents, together with the estimated net proceeds from the TuHURA Note Financing, will be sufficient to meet its anticipated cash requirements through the end of 2025.

Management Comments

• Management based projections of operating capital requirements on TuHURAs current operating plan, which includes several assumptions that may prove to be incorrect.
• Management believes that its existing cash and cash equivalents, together with the estimated net proceeds from the TuHURA Note Financing, will be sufficient to meet its anticipated cash requirements through the end of 2025.

Industry Context

This announcement reflects the ongoing trend of biotech companies merging to consolidate resources and expertise. The focus on immuno-oncology and personalized cancer vaccines aligns with current industry trends in cancer treatment. The company's reliance on private funding and the need for additional capital is common in the biotech sector, especially for companies in the clinical stage of development.

Comparison to Industry Standards

• TuHURA's financial situation, with significant losses and reliance on private funding, is typical for clinical-stage biotech companies. For example, companies like Adaptimmune Therapeutics and Gritstone Bio also experience substantial losses while developing their therapies.
• The company's focus on personalized cancer vaccines is similar to companies like BioNTech and Moderna, although TuHURA is at an earlier stage of development.
• The merger with Kintara is a strategic move to gain access to public markets, similar to other biotech companies that have used reverse mergers to go public, such as Cassava Sciences.
• The $5 million exclusivity payment to Kineta is a significant investment, but it is not uncommon for biotech companies to make such payments for promising assets, similar to licensing deals seen in the industry.
• The planned Phase 3 trial for IFx-2.0 is a critical step, and its success will be crucial for the company's future, similar to other companies that have reached this stage, such as Incyte with its various clinical trials.

Stakeholder Impact

• Shareholders face the risk of dilution due to potential future equity offerings.
• Employees may be impacted by the company's financial performance and potential need for cost-cutting measures.
• Customers (potential patients) may benefit from the development of new cancer treatments, but there is no guarantee of success.
• Suppliers and creditors may be impacted by the company's ability to pay its obligations.
• The merger with Kintara and the potential acquisition of KVA12123 could have a positive impact on the company's future prospects.

Next Steps

• TuHURA plans to initiate a Phase 3 trial for IFx-2.0 in the first quarter of 2025.
• The company will continue to develop its product candidates and seek regulatory approvals.
• TuHURA will need to secure additional funding to support its operations and growth strategy.
• The company will continue to collaborate with Kineta on the ongoing KVA12123 VISTA clinical trial program.

Key Dates

Keywords

immuno-oncology, cancer vaccine, antibody drug conjugates, clinical trials, merger, FDA, IFx-2.0, KVA12123, convertible notes, capital raise